Find Reports

Select Report Type

Reimbursement Review

Displaying 426 - 450 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
buprenorphine	Sublocade	buprenorphine	SR0579 Sublocade - CDEC Final Recommendation June 21, 2019_for posting.pdf sr0579-sublocade-clinical-review-report.pdf sr0579-sublocade-pharmacoeconomic-review-report.pdf	Opioid use disorder, treatment	Reimburse with clinical criteria and/or conditions	Complete	Dec 20, 2018	Jun 19, 2019	SR0579-000
cysteamine	Cystadrops	cysteamine	SR0595 Cystadrops - CDEC Final Recommendation June 20, 2019_for posting.pdf sr0595-cystadrops-clinical-review-report.pdf sr0595-cystadrops-pharmacoeconomic-review-report.pdf	Corneal cystine crystal deposits	Reimburse with clinical criteria and/or conditions	Complete	Dec 10, 2018	Jun 18, 2019	SR0595-000
Venclexta in combo Rituximab f...	Venclexta in combo Rituximab	Venetoclax	pcodr_provfund_10162_venetoclax_venclexta_and_rituximab.pdf 10162VenetoclaxRituximabCLL_FnRec_approvedbyChair_REDACT_Post_31May2019-final.pdf 10162VenetoclaxRituximabCLL_fnEGR_NOREDACT-ABBREV_31May2019_final.pdf 10162VenetoclaxRituximabCLL_fnCGR_REDACT_Post_31May2019_final.pdf 10162VenetoclaxRituximabCLL_InRec_POST04Apr2019_REDACT_final.pdf 10162VenetoclaxRituximabCLL_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf 10162VenetoclaxRituximabCLL_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf 10162VenetoclaxRituximabCLL_PatientFeedback_LC_CLLPAG_2019-04-17_Post_31May2019_final.pdf 10162VenetoclaxRituximabCLL_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf 10162VenetoclaxRituximabCLL_Patient_Combined_COIs_Post_31May2019_final.pdf 10162VenetoclaxRituximabCLL_Clinician_Combined_COIs_Post_31May2019_final.pdf	Chronic Lymphocytic Leukemia (CLL)	Reimburse with clinical criteria and/or conditions	Complete	Oct 24, 2018	May 31, 2019	PC0162-000
Vizimpro for Non-Small Cell Lu...	Vizimpro	Dacomitinib	pcodr-provfund-10129-dacomitinib-vizimpro.pdf 10129DacomitinibNSCLC_FnRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf 10129DacomitinibNSCLC_fnEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf 10129DacomitinibNSCLC_fnCGR_NOREDACT_Post_31May2019_final.pdf 10129DacomitinibNSCLC_InRec_POST04Apr2019_NOREDACT_final.pdf 10129DacomitinibNSCLC_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf 10129DacomitinibNSCLC_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf 10129DacomitinibNSCLC_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf 10129DacomitinibNSCLC_Patient_Combined_COIs_ForPosting_31May2019_final.pdf 10129DacomitinibNSCLC_Clinician_Combined_COIs_Post_31May2019_final.pdf	Non-Small Cell Lung Cancer	Reimburse with clinical criteria and/or conditions	Complete	Sep 19, 2018	May 31, 2019	PC0129-000
Keytruda for Non-Squamous NSCL...	Keytruda	Pembrolizumab	pcodr-provfund-10153-pembrolizumab-keytruda-non-squamous_nsclc.pdf 10153PembroNSQ-NSCLC_FnRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf 10153PembroNSQ-NSCLC_fnEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_fnCGR_REDACT_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_InRec_POST04Apr2019_NOREDACT_corrected.pdf 10153PembroNSQ-NSCLC_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_Patient_Combined COIs_ForPosting_31May2019.pdf 10153PembroNSQ-NSCLC_Clinician_Combined COIs_Post_31May2019_final.pdf	Nonsquamous NSCLC	Reimburse with clinical criteria and/or conditions	Complete	Sep 14, 2018	May 31, 2019	PC0153-000
risankizumab	Skyrizi	risankizumab	TS0001-PsO-Updated-Streamlined-Rec.pdf SR0583 Skyrizi - CDEC Final Recommendation May 28, 2019_For posting.pdf sr0583-skyrizi-clinical-review-report.pdf sr0583-skyrizi-pharmacoeconomic-review-report.pdf sr0583-risankizumab-patient-input.pdf	Psoriasis, moderate to severe plaque	Reimburse with clinical criteria and/or conditions	Complete	Oct 22, 2018	May 28, 2019	SR0583-000
Xalkori for ROS1-positive adva...	Xalkori	Crizotinib	pcodr-provfund-10151-crizotinib-xalkori-ROS-positive.pdf 10151CrizotinibNSCLC_fnRec_EC_approvedbyChair_Post_23May2019_final_cleaned.pdf 10151CrizotinibNSCLC_fnEGR_EC_NOREDACT-ABBREV_Post_23May2019_final.pdf 10151CrizotinibNSCLC_fnCGR_EC_NOREDACT_Post_23May2019_final.pdf 10151CrizotinibNSCLC_inRec_03May2019_approvedbyChair_Post_03May2019_final.pdf 10151CrizotinibNSCLC_PAGFeedbackSummary_Post_23May2019_final_cleaned.pdf 10151CrizotinibNSCLC_SubmitterFeedback_2019-05-17_Post_23May2019_final_cleaned.pdf 10151CrizotinibNSCLC_PatientFeedback_LCC_2019-05-17_Post_23May2019_final_cleaned.pdf 10151CrizotinibNSCLC_ClinicianFeedback_LCC_2019-05-17_Post_23May2019_final_cleaned.pdf 10151CrizotinibNSCLC_Combined_COIs_Post_23May2019.pdf 10151CrizotinibNSCLC_Combined_COI_Post_23May2019_final_Redacted.pdf	ROS1-positive advanced non-small cell lung cancer (NSCLC)	Reimburse with clinical criteria and/or conditions	Complete	Oct 30, 2018	May 23, 2019	PC0151-000
cerliponase alfa	Brineura	cerliponase alfa	SR0574 Brineura - Final CDEC Recommendation May 27, 2019_for posting.pdf sr0574-brineura-clinical-review-report.pdf sr0574-brineura-pharmacoeconomic-review-report.pdf sr0574-brineura-patient-input.pdf	Neuronal Ceroid Lipofuscinosis Type 2	Reimburse with clinical criteria and/or conditions	Complete	Jul 31, 2018	May 23, 2019	SR0574-000
efinaconazole	Jublia	efinaconazole	SR0577 Jublia - CDEC Final Recommendation May 27, 2019_for posting.pdf sr0577-jublia-clinical-review-report.pdf sr0577-jublia-pharmacoeconomic-review-report.pdf sr0577-jublia_patient-input.pdf	Onychomycosis	Do not reimburse	Complete	Aug 2, 2018	May 23, 2019	SR0577-000
semaglutide	Ozempic	semaglutide	Recommendation and Reasons: Updated Recommendation and Reasons: Original Clinical Report Pharmacoeconomic Report Patient Group Input Submissions	Diabetes mellitus, type 2	Reimburse with clinical criteria and/or conditions	Complete	Nov 23, 2018	May 15, 2019	SR0594-000
isavuconazole	Cresemba	isavuconazole	SR0586 Cresemba - CDEC Final Recommendation May 17, 2019_for posting.pdf sr0586-cresemba-clinical-review-report.pdf sr0586-cresemba-pharmacoeconomic-review-report.pdf	Treatment of invasive aspergillosis and mucormycosis	Reimburse with clinical criteria and/or conditions	Complete	Nov 2, 2018	May 15, 2019	SR0586-000
doravirine lamuvidine tenofovi...	Delstrigo	doravirine lamuvidine tenofovir disoproxil fumarate	SR0581 Delstrigo - CDEC Final Recommendation May 16, 2019 for posting.pdf SR0581 Delstrigo - Patient Input for Posting.pdf sr0581-delstrigo-cdr-new-combination-report.pdf	HIV-1 infection	Reimburse with clinical criteria and/or conditions	Complete	Nov 16, 2018	May 14, 2019	SR0581-000
doravirine	Pifeltro	doravirine	SR0582 Pifeltro - CDEC Final Recommendation May 16, 2019 for posting.pdf sr0582-pifeltro-clinical-review-report.pdf sr0582-pifeltro-pharmacoeconomic-review-report.pdf sr0582-pifeltro-patient-input.pdf	HIV-1 infection	Reimburse with clinical criteria and/or conditions	Complete	Nov 16, 2018	May 14, 2019	SR0582-000
Tafinlar & Mekinist in com...	Tafinlar & Mekinist in combo	Dabrafenib & Trametinib in combo	pcodr-provfund_10152_dabrafenib_trametinib_and_tafinlar_mekinist.pdf 10152DabrafenibTrametinibMAT_Final Recc_Approved by Chair_2May2019_REDACT_Post_03May2019_final.pdf 10152DabrafenibTrametinibMAT_fnEGR_NOREDACT-ABBREV_Post_03May2019_final.pdf 10152DabrafenibTrametinibMAT_fnCGR_REDACT_Post_03May2019_final.pdf 10152 Dabrafenib-Trametinib MAT_inRec_Approved by Chair_REDACT_Post_07Mar2019_final.pdf 10152DabrafenibTrametinibMAT_PAGFeedbackSummary_FINAL_Post_03May2019_final.pdf 10152DabrafenibTrametinibMAT_SubmitterFeedback_2019-03-12_Post_03May2019_final.pdf 10152DabrafenibTrametinibMAT_ClinicianFeedback_CCO_2019-03-14_Post_03May2019_final.pdf 10152DabrafenibTrametinibMAT_PatientCOI_Combined_Post_03May2019_final_Redacted.pdf 10152DabrafenibTrametinibMAT_ClinicianCOI_Combined_Post_03May2019_final_Redacted.pdf	Melanoma Adjuvant Therapy	Reimburse with clinical criteria and/or conditions	Complete	Sep 21, 2018	May 3, 2019	PC0152-000
Imfinzi for Non-Small Cell Lun...	Imfinzi	Durvalumab	pcodr_profund_durvalumabImfinzi_nsclc.pdf 10131DurvalumabNSCLC_fnRec_02May2019_approvedbyChair_Post_03May2019_final.pdf 10131DurvalumabNSCLC_fnEGR_NOREDACT-ABBREV_Post_03May2019_final.pdf 10131DurvalumabNSCLC_fnCGR_NOREDACT_Post_03May2019_final.pdf 10131DurvalumabNSCLC_inRec_approvedbyChair_06Mar2019_Post_07Mar2019_final.pdf 10131DurvalumabNSCLC_PAGFeedbackSummary_FINAL_Post_03May2019_final.pdf 10131DurvalumabNSCLC_SubmitterFeedback_2019-03-21_Post_03May2019_final.pdf 10131DurvalumabNSCLC_ClinicianFeedback_CCO_2019-03-21_Post_03May2019_final.pdf 10131DurvalumabNSCLC_Combined_PatientCOI_2018-10-05_Post_03May2019_final_Redacted.pdf 10131DurvalumabNSCLC_Combined_ClinicianCOI_Post_03May2019_final_Redacted.pdf	Unresectable Non-Small Cell Lung Cancer (NSCLC)	Reimburse with clinical criteria and/or conditions	Complete	Sep 21, 2018	May 3, 2019	PC0131-000
Ibrance (with Faslodex) for Ad...	Ibrance (with Faslodex)	Palbociclib (with Fulvestrant)	pcodr_provfund-10150-ibrance-faslodex-mbc.pdf 10150 PalbociclibFulvestrantMBC_fnRec_2019-05-03_Approved_Post_03May2019_final.pdf 10150PalbociclibFulvestrantMBC_fnEGR_NOREDACT-ABBREV_Post_03May2019_final.pdf 10150PalbociclibFulvestrantMBC_fnCGR_NOREDACT_Post_03May2019_final.pdf 10150PalbociclibFulvestrantMBC_inRec_2019-03-06_ChairApproved_NOREDACT_Post_07Mar2019_final.pdf 10150PalbociclibFulvestrantMBC_PAGFeedbackSummary_FINAL_Post_03May2019_final.pdf 10150PalbociclibFulvestrantMBC_SubmitterFeedback_2019-03-21_Post_03May2019_final.pdf 10150PalbociclibFulvestrantMBC_ClinicianFeedback_CCO_2019-03-22_Post_03May2019_final.pdf 10150PalbociclibFulvestrantMBC_Combined_PatientCOI_RBC_Posting_03May2019_Redacted_final.pdf 10150PalbociclibFulvestrantMBC_Combined_ClinicianICOI_Post_03May2019_final_Redacted.pdf	Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Sep 28, 2018	May 3, 2019	PC0150-000
Blincyto for Philadelphia Chro...	Blincyto	Blinatumomab	pcodr_profung_10146_blinatumomab_blincyto-all.pdf 10146BlinatumomabPh+ALL_FnCGR_04April2019_REDACT_POST_final.pdf 10146BlinatumomabPh+ALL_FnRec_04Apr2019_REDACT_post_final.pdf 10146BlinatumomabPh+ALL_fnEGR_NOREDACT-ABBREV_POST04Apr2019_final.pdf 10146_BlinatumomabPh+ALL_InRec_AprovedbyChair_REDACT_31Jan2019_final.pdf 10146Blinatumomab_Ph+ALL_PAGFeedbackSummary_FINAL_Post_04Apr2019_final.pdf 10146BlinatumomabPh+ALL_SubmitterFeedback_2019-02-19_Post_04Apr2019_final.pdf 10146BlinatumomabPh+ALL_ClinicianFeedback_CCO_2019-02-14_Post_04Apr2019_final.pdf 10146BlinatumomabPh+ALL_PatientGroupCOI_LLSC_2018-09-14_final.pdf 10146BlinatumomabPh+ALL_ClinicianInputCOI_Combined_04Apr2019_post_final.pdf	Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)	Reimburse with clinical criteria and/or conditions	Complete	Aug 31, 2018	Apr 4, 2019	PC0146-000
Folotyn for Peripheral T-Cell ...	Folotyn	Pralatrexate	pcodr_provfund_10138_pralatrexate_folotyn.pdf 10138PralatrexatePTCL_fnRec__04Apr2019_NOREDACT_post_final2.pdf 10138PralatrexatePTCL_fnCGR_NOREDACT_POST04Apr2019_final.pdf 10138PralatrexatePTCL_fnEGR_NOREDACT-ABBREV_POST04Apr2019_final.pdf 10138PralatrexatePTCL_InRec_31Jan2019_approvedbyChair_final.pdf 10138Pralatrexate_PTCL_PAGFeedbackSummary_FINAL_Post_04Apr2019_final.pdf 10138PralatrexatePTCL_SubmitterFeedback_2019-02-14_Post_04Apr2019_final.pdf 10138PralatrexatePTCL_PatientFeedback_LC_2019-02-14_Post_04Apr2019_final.pdf 10138PralatrexatePTCL_ClinicianFeedback_CCO_2019-02-14_Post_04Apr2019_final.pdf 10138PralatrexatePTCL_PatientCOI_LC_2018-06-15_Post_04Apr2019_final.pdf 10138PralatrexatePTCL_ClinicianCOI_Combined_Post_final.pdf	Peripheral T-Cell Lymphoma (PTCL)	Reimburse with clinical criteria and/or conditions	Complete	Jun 1, 2018	Apr 4, 2019	PC0138-000
reslizumab	Cinqair	reslizumab	sf0591-cinqair-request-for-advice.pdf sf0591-cinqair-patient-input.pdf sf0591-cinqair-cdec-rec-march-29-19.pdf	Asthma, eosinophilic	Reimburse with clinical criteria and/or conditions	Complete	Oct 24, 2018	Mar 27, 2019	SF0591-000
benralizumab	Fasenra	benralizumab	sf0592-fasenra-request-for-advice.pdf sf0592-fasenra-patient-input.pdf sf0592-fasenra-cdec-rec-march-29-19.pdf	Asthma, severe eosinophilic	Reimburse with clinical criteria and/or conditions	Complete	Oct 24, 2018	Mar 27, 2019	SF0592-000
mepolizumab	Nucala	mepolizumab	sf0593-nucala-request-for-advice.pdf sf0593-nucala-patient-input.pdf sf0593-nucala-cdec-rec-march-29-19.pdf	Asthma, severe eosinophilic	Reimburse with clinical criteria and/or conditions	Complete	Oct 24, 2018	Mar 27, 2019	SF0593-000
crisaborole	Eucrisa	crisaborole	SR0570-Eucrisa-cdec-rec-april-2-2019.pdf sr0570-eucrisa-clinical-report.pdf sr0570-eucrisa-pharmacoeconomic-report.pdf SR0570-eucrisa-patient-input.pdf	atopic dermatitis	Do not reimburse	Complete	May 25, 2018	Mar 27, 2019	SR0570-000
edaravone	Radicava	edaravone	sr0573-radicava-clinical-review-report.pdf sr0573-radicava-pharmacoeconomic-review-report.pdf sr0573_radicava-patient-input.pdf sr0573-radicava-cdec-rec-march-29-2019.pdf	amyotrophic lateral sclerosis	Reimburse with clinical criteria and/or conditions	Complete	Jul 5, 2018	Mar 27, 2019	SR0573-000
Xtandi for non-metastatic Cast...	Xtandi	Enzalutamide	pcodr_profund_enzalutamide_xtandi_non-mcrpc_10149.pdf 10149Enzalutamidenm-CRPC_FnRec_EarlyConv_2019-03-26-v4_Post_26Mar2019_final.pdf 10149Enzalutamidenm-CRPC_fnCGR_EC_Post_26Mar2019_final.pdf 10149Enzalutamidenm-CRPC_fnEGR_EC_NOREDACT-ABBREV_Post_26Mar2019_final.pdf 10149Enzalutamidenm-CRPC_InRec_approvedbyChair_NOREDACT_Post_07Mar2019_final.pdf 10149Enzalutamide_nmCRPC_PAGFeedbackSummary_FINAL_Post_26Mar2019_final.pdf 10149Enzalutamidenm-CRPC_SubmitterFeedback_2019-03-21_Post_26Mar2019_final.pdf 10149Enzalutamidenm-CRPC_ClinicianFeedback_CCO_2019-03-21_Post_26Mar2019_final.pdf 10149Enzalutamide-CRPC_COI_CCSN_Post_26Mar2019_final_Redacted.pdf 10149EnzalutamidenmCRPC_Combined_Clinician_COI_Post_26Mar2019_final.pdf	Non-metastatic castration-resistant prostate cancer (nm-CRPC)	Reimburse with clinical criteria and/or conditions	Complete	Sep 24, 2018	Mar 26, 2019	PC0149-000
Unituxin for Neuroblastoma – D...	Unituxin	Dinutuximab	pcodr-provfund-10154-dinutuximab-unituxin-neuroblastoma.pdf 10154DinutuximabNeuroblastoma_fnRec_EC_ApprovedbyChair_2019-03-26_Post_26Mar2019_final.pdf 10154DinutuximabNeuroblastoma_fnCGR_ECPost_26Mar2019_final.pdf 10154DinutuximabNeuroblastoma_fnEGR_NOREDACT-ABBREV_Post_26Mar2019_final.pdf 10154DinutuximabNeuroblastoma_inRec_approvedbyChair_05Mar2019_Post_07Mar2019_final.pdf 10154Dinutuximab_Neuroblastoma_PAGFeedback_FINAL_Post_26Mar2019_final.pdf 10154DinutuximabNeuroblastoma_ClinicianFeedback_POGO_2019-03-21_Post_26Mar2019_final.pdf 10154Dinutuximab_Neuroblastoma_COI_Ac2orn_2018-10-15_Post_26Mar2019_final_Redacted.pdf 10154Dinutuximab_NeuroblastomaCombined_Clinician COI_Post_26Mar2019_final.pdf	Neuroblastoma	Reimburse with clinical criteria and/or conditions	Complete	Oct 1, 2018	Mar 26, 2019	PC0154-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 426 - 450 of 600

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Screening Tools for Chronic Postsurgical Pain: A Review of Clinical Utility	RC1329 CPSP v.8.0.pdf	Jan 15, 2021	Summary with Critical Appraisal	Completed	RC1329-000
Codeine for Acute Extremity Pain: A Review of Clinical Effectiveness	Codeine for Acute Extremity Pain: A Review of Clinical Effectiveness	Jan 12, 2021	Summary with Critical Appraisal		RC1324-000
Coverage Categories at Public Drugs Plans in Canada		Dec 18, 2020			ES0353-000
Latent Tuberculosis Infection Testing in People with Compromised Immunity Prior to Biologic Therapy: A Review of Diagnostic Accuracy, Clinical Utility, and Guidelines	Latent Tuberculosis Infection Testing in People with Compromised Immunity Prior…	Dec 14, 2020	Rapid Review	Completed	RC1316-000
Codeine for Pain Related to Osteoarthritis of the Knee and Hip: A Review of Clinical Effectiveness	Codeine for Pain Related to Osteoarthritis of the Knee and Hip: A Review of Cli…	Dec 14, 2020	Summary with Critical Appraisal	Completed	RC1323-000
Brivaracetam versus Levetiracetam for Epilepsy: A Review of Comparative Clinical Safety	RC1322 Comparing 2 Antiepileptic Drugs Final.pdf	Dec 14, 2020	Summary with Critical Appraisal		RC1322-000
Rapid and Simultaneous Tuberculosis and Antibiotic Susceptibility Testing for the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance: A Review of Diagnostic Accuracy	Summary with Critical Appraisal - Rapid Response	Dec 10, 2020	Summary with Critical Appraisal	Completed	RC1317-000
Care Coordination and Funding of Pediatric Cerebral Palsy in Canada		Dec 8, 2020	Environmental Scan	Completed	ES0340-000
Coverage Categories at Public Drugs Plans in Canada		Dec 8, 2020	Environmental Scan	Completed	ES0353-000
Direct Observational Therapy for the Treatment of Tuberculosis: A Review of Clinical Evidence and Guidelines	RC1312 DOT for TB Final.pdf	Dec 7, 2020	Summary with Critical Appraisal	Completed	RC1312-000
Care Coordination and Funding of Pediatric Cerebral Palsy in Canada — Project Report		Dec 7, 2020	Environmental Scan	Completed	ES0340-000
Dialectical Behaviour Therapy for People with Borderline Personality Disorder: A Rapid Qualitative Review	RC1320 DBT for BPD qual Final.pdf	Nov 26, 2020	Summary with Critical Appraisal	Completed	RC1320-000
PET Diagnostic Imaging with Prostate-Specific Membrane Antigen for Prostate Cancer: A Review of Clinical Utility, Cost-Effectiveness, Diagnostic Accuracy, and Guidelines	RC1321 PSMA for Prostate Cancer Final.pdf	Nov 26, 2020	Summary with Critical Appraisal	Completed	RC1321-000
Trastuzumab Combination and Monotherapy for HER2 Advanced or Recurrent Uterine or Endometrial Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness	RC1319 Trastuzumab for USC Final.pdf	Nov 26, 2020	Summary with Critical Appraisal	Completed	RC1319-000
Target-Controlled Infusion with Propofol and Remifentanil for Moderate Procedural Sedation in Medicine and Dentistry: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1315 TCI with Propofol and Remifentanil Final.pdf	Nov 16, 2020	Summary with Critical Appraisal	Completed	RC1315-000
Care for Acquired Brain Injury and Concurrent Mental Health and Substance Use Issues		Nov 5, 2020			ES0339-000
Patient Positioning During a Hypotensive Episode for Adults Undergoing Hemodialysis: A Review of Clinical Effectiveness and Guidelines	RC1308 Patient Positioning during Hemodialysis Final.pdf	Nov 2, 2020	Summary with Critical Appraisal		RC1308-000
Outpatient or Short Stay Total Hip or Knee Arthroplasty versus Conventional Total Hip or Knee Arthroplasty: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines	Outpatient or Short Stay Total Hip or Knee Arthroplasty versus Conventional Tot…	Oct 28, 2020	Summary with Critical Appraisal	Completed	RC1313-000
Intravenous Multivitamin Therapy Use in Hospital or Outpatient Settings: A Review of Clinical Effectiveness and Guidelines	RC1310 IV Multivitamins Final.pdf	Oct 26, 2020	Summary with Critical Appraisal		RC1310-000
Rapid Point-of-Care Antigen Testing for SARS-CoV-2 Infection	Rapid Point-of-Care Antigen Testing for SARS-CoV-2 Infection	Oct 20, 2020	Health Technology Update		EN0025-000
Care for Acquired Brain Injury and Concurrent Mental Health Conditions and/or Substance Use Disorders	es0339-care-for-acquired-brain-injury.pdf	Oct 15, 2020			ES0339-000
Transcatheter Aortic Valve Implantation for Degenerated Mitral or Tricuspid Bioprostheses: A Review of Clinical Effectiveness and Cost-Effectiveness	RD0057 TAVI 2 Final.pdf	Oct 13, 2020	Peer-reviewed Summary with Critical Appraisal	Completed	RD0057-000
Ventilation and Perfusion Imaging for the Diagnosis of Pulmonary Embolisms During the COVID-19 Pandemic: A Review of Safety and Guidelines	Ventilation and Perfusion Imaging for the Diagnosis of Pulmonary Embolisms Duri…	Oct 6, 2020	Rapid Review	Completed	RC1309-000
Wearable Devices for Monitoring and Detecting COVID-19 Symptoms	Wearable Devices for Monitoring and Detecting COVID-19 Symptoms	Sep 30, 2020	Health Technology Update	Completed	EN0021-000
Interventions for the Prevention of Sudden Infant Death Syndrome and Sudden Unexplained Death in Infancy: A Review of Guidelines	RC1307 SIDS Prevention Final.pdf	Sep 28, 2020	Summary with Critical Appraisal		RC1307-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 426 - 450 of 2132

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
ibrutinib			May 21, 2024	Reimbursement Review		Not filed	NS0005-000
ibrutinib			May 21, 2024	Reimbursement Review		Not filed	NS0004-000
Newborn Screening for Congenital Cytomegalovirus		Newborn Screening for Congenital Cytomegalovirus	May 17, 2024	Health Technology Review	Rapid Review	Completed	RC1533-000
Exploration of the Risk of Suicidality and Self-Harm With Glucagon-Like Peptide-1 Receptor Agonists		Exploration of the Risk of Suicidality and Self-Harm With Glucagon-Like Peptide…Final Summary Report	May 16, 2024	Health Technology Review	Technology Review	Completed	HC0087-000
letermovir			May 14, 2024	Reimbursement Review		Withdrawn	SR0824-000
odevixibat		Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	May 10, 2024	Reimbursement Review		Complete	SR0788-000
Use of MRI and CT in Private Imaging Facilities in Canada (2021-2023)		Use of MRI and CT in Private Imaging Facilities in Canada (2021-2023)	May 7, 2024	Health Technology Review	CMII Service	Completed	CM0010-000
General Ultrasound Examination Volumes per Sonographer 8-Hour Workday		General Ultrasound Examination Volumes per Sonographer 8-Hour Workday	May 7, 2024	Health Technology Review	CMII Service	Completed	CM0012-000
nivolumab and relatlimab		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	May 7, 2024	Reimbursement Review		Complete	PC0329-000
Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma		Final Recommendation and Reason Updated Reimbursement Recommendations Final Summary Report Feedback on Draft Updated Reimbursement Recommendations Patient Group Input Submission Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma - Project Pr…	May 6, 2024	Reimbursement Review	Therapeutic Review	Complete	TR0014-000 - OP0547-000
Outpatient Nirmatrelvir-Ritonavir and Remdesivir Utilization in Canada		Final Report, April 2024 Summary Report, April 2024	May 3, 2024	Health Technology Review	Technology Review	Completed	HC0069-000
Artificial Intelligence for Patient Flow	Our Horizon Scan explores artificial intelligence-based patient flow management tools that forecast and monitor patient movements from admission to discharge as they progress through different care settings.	Artificial Intelligence for Patient Flow	May 2, 2024	Horizon Scan	Emerging Health Technologies	Completed	EH0125-000
Efficacy and Safety of Long-Term Use of Omalizumab for the Treatment of Chronic Idiopathic Urticaria		Final Report Final Summary Report Project Protocol	May 2, 2024	Health Technology Review	Systematic Review	Active	RE0043-000
Halobetasol propionate and tazarotene		SR0638 Duobrii - CDEC Final Recommendation October 30, 2020_For Posting.pdf sr0638-duobrii-clinical-review-report.pdf sr0638-duobrii-parmacoeconomic-review-report.pdf SR0638 Duobrii - Patient Input_For posting.pdf	May 2, 2024	Reimbursement Review		Complete	SR0638-000
difelikefalin		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Apr 30, 2024	Reimbursement Review		Complete	SR0752-000
tisagenlecleucel		Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Apr 30, 2024	Reimbursement Review		Complete	PG0306-000
crisantaspase recombinant		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Apr 30, 2024	Reimbursement Review		Complete	PC0301-000
niraparib abiraterone acetate		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Apr 29, 2024	Reimbursement Review		Complete	PC0326-000
olaparib		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Apr 25, 2024	Reimbursement Review		Complete	PC0319-000
Pharmaceutical Reviews Update — Issue 46			Apr 24, 2024	Reimbursement Review	Pharmaceutical Review Update
glofitamab		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Apr 22, 2024	Reimbursement Review		Complete	PC0320-000
SGLT2 inhibitors for the treatment of type 2 diabetes			Apr 18, 2024	Health Technology Review	Technology Review	Cancelled	HC0049-000
evinacumab		Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Apr 17, 2024	Reimbursement Review		Complete	SR0778-000
Buprenorphine-Based Formulations for Opioid Use Disorder in Correctional Settings	Various formulations of buprenorphine, including extended-release depot injection and transmucosal tablet and film, are used to treat opioid use disorder. Our Environmental Scan explores the provision of these formulations in correctional settings.	Final Report Summary report	Apr 15, 2024	Horizon Scan	Environmental Scan	Complete	ES0380-000
imiquimod			Apr 15, 2024	Reimbursement Review		Withdrawn	PX0364-000